Angiotensin receptor autoantibodies as biomarker for effected usage of angiotensin receptor blockers
AssigneeThe Johns Hopkins University
InventorsJeremy D. Walston, Peter M. Abadir, Alka Jain, Neal Fedarko
Life of this patent
Estimating the term…
Abstract
The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies arc identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
Claims14
(canceled)
A method of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker, comprising determining the level of angiotensin receptor autoantibodies in a patient sample compared to a reference standard, wherein a higher level of angiotensin receptor autoantibodies in the patient sample compared to a reference standard indicates that the patient may benefit from treatment with an angiotensin receptor blocker.
(canceled)
Dependencies are inferred from the claim text.